These Analysts Revise Their Forecasts On Restaurant Brands After Q3 Results

Restaurant Brands International Inc (NYSE: QSR) reported weaker-than-expected third-quarter sales on Friday.

Restaurant Brands International Inc (NYSE:QSR) reported weaker-than-expected third-quarter sales on Friday.

Restaurant Brands reported third-quarter FY23 sales growth of 6.4% year-on-year to $1.837 billion, missing the analyst consensus estimate of $1.874 billion. Adjusted EPS of $0.90 beat the consensus estimate of $0.86.

Restaurant Brands’ Board of Directors declared a dividend of $0.55 per common share, payable on January 4, 2024, to shareholders of record on December 21, 2023.

Restaurant Brands shares fell 2.4% to trade at $66.20 on Monday.

These analysts made changes to their price targets on Restaurant Brands following earnings announcement.

  • Keybanc cut the price target on Restaurant Brands from $85 to $82. Keybanc analyst Eric Gonzalez maintained an Overweight rating.
  • Truist Securities slashed the price target on Restaurant Brands from $89 to $83. Truist Securities analyst Jake Bartlett maintained a Buy rating.
  • RBC Capital, meanwhile, raised the price target on Restaurant Brands from $86 to $87. RBC Capital analyst Christopher Carril maintained an Outperform rating.

Check This Out: Top 5 Health Care Stocks That May Fall Off A Cliff This Month

Total
0
Shares
Related Posts
Read More

Cogent Biosciences Announced Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosisl; Announced 89% ORR in TKI-therapy Naïve Patients; 73% ORR in All Evaluable Patients with 27-wee…

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated clinical data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic m

COGT